Comparing indocyanine green doses to view blood vessels in revisional weight loss surgery
Tests different doses of a green dye to see blood flow in adults with obesity.
Plain-language title generated from the registry record
Registry title: Indocyanine Green Fluorescence Angiography (ICG-FA) in Revisional Bariatric Surgery
Key facts
- Where
- Tijuana, MexicoSee the site
Where in Mexico
- Centro Medico BariatricoTijuana, MexicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto Mexicano del Seguro Social
- Trial code
- NCT07000539
- Record updated
- 27 March 2026
- Original description
This study will compare different doses of a green fluorescent product that is administered during weight loss surgery in order to observe where blood vessels are located. There is uncertainty around the optimal dose of this product for patients with obesity, so this study will aim to study if the dose in the minimal range recommended by international guidelines is sufficient for most patients or if higher doses are needed with increasing body mass index.Read full original descriptionShow less
Prospective Single-center Diagnostic Parallel-group Study to Determine the Minimal Dose of Indocyanine Green to Observe Vascular Perfussion in Revisional Bariatric Surgery.
This study will compare different doses of a green fluorescent product that is administered during weight loss surgery in order to observe where blood vessels are located. There is uncertainty around the optimal dose of this product for patients with obesity, so this study will aim to study if the dose in the minimal range recommended by international guidelines is sufficient for most patients or if higher doses are needed with increasing body mass index.
Inclusion: Diagnosis of obesity with a BMI ≥ 30 kg/m²; Scheduled for revisional bariatric surgery.
Exclusion: Allergy to iodides; Anticoagulation with products containing sodium bisulfite (due to the risk of ICG-FA inactivation); History of liver disease or laboratory findings suggestive of moderate to severe hepatic disease: total bilirubin >1.5 times the upper limit of normal (ULN), or any elevation of aspartate aminotransferase (AST) above ULN; Use of radioactive iodine studies within the past 7 days; Pregnant, breastfeeding, or planning to become pregnant within the next year (due to unknown teratogenic or fertility effects of ICG-FA); Participants who withdraw their consent to participate in the study (elimination criterion).